FDOPA PET/CT has a Significant Clinical Impact on the Management of Patients with Neuroendocrine Tumors

#365

Introduction: Studies suggest that positron emission tomography (PET) using the dopamine-synthesis tracer [18F]fluoro-dihydroxyphenylalanine (FDOPA) may improve the clinical management of patients with NET.

Aim(s): To evaluate the clinical impact of FDOPA PET/CT on the management of patients evaluated for NET.

Materials and methods: 80 patients were included (47 females; 33 men), 30 of whom had no prior history of NET and 50 of whom had previously been treated for NET. The clinical impact of FDOPA PET/CT was evaluated by comparison with somatostatin receptor scintigraphy (SRS) and contrast-enhanced CT.

Conference:

Presenting Author:

Authors: Sørensen M, Trägårdh M, Rudbeck A, Grønbæk H,

Keywords: positron emission tomography, somatostatin receptor scintigraphy, neuroendocrine,